RT Journal Article
SR Electronic
T1 Mutations in emerging variant of concern lineages disrupt genomic sequencing of SARS-CoV-2 clinical specimens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.01.21258181
DO 10.1101/2021.06.01.21258181
A1 Kuchinski, Kevin S.
A1 Nguyen, Jason
A1 Lee, Tracy D.
A1 Hickman, Rebecca
A1 Jassem, Agatha N.
A1 Hoang, Linda M. N.
A1 Prystajecky, Natalie A.
A1 Tyson, John R.
YR 2021
UL http://medrxiv.org/content/early/2021/06/04/2021.06.01.21258181.abstract
AB Mutations in emerging SARS-CoV-2 lineages can interfere with the laboratory methods used to generate high-quality genome sequences for COVID-19 surveillance. Here, we identify 46 mutations in current variant of concern lineages affecting the widely used laboratory protocols for SARS-CoV-2 genomic sequencing by Freed et al. and the ARTIC network. We provide laboratory data showing how three of these mutations disrupted sequencing of P.1 lineage specimens during a recent outbreak in British Columbia, Canada, and we also demonstrate how we modified the Freed et al. protocol to restore performance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWork was supported in part by the Canadian COVID genomics network (CanCOGeN).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was conducted under a surveillance mandate, authorized by the Provincial Health Officer of British Columbia under the Health Act, without requirement for research ethics board review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLaboratory protocols cited where relevant. Details and accession numbers of GISAID sequences analyzed are included as supplementals.